About 100 reports

  • HEART TRANSPLANT REJECTION - PIPELINE BY HEAT BIOLOGICS INC, H2 2017
  • PTX-15 - DRUG PROFILE

Heart transplant replaces an injured or diseased heart with a healthy one.

  • Heart Transplant
  • Medical Biotechnology
  • Targeted Therapy
  • Transplantation
  • Astellas Pharma Inc.
  • HEART TRANSPLANT REJECTION - PIPELINE BY HEAT BIOLOGICS INC, H1 2018
  • HEART TRANSPLANT REJECTION - PIPELINE BY NOXXON PHARMA AG, H1 2018

Heart transplant replaces an injured or diseased heart with a healthy one.

  • Heart Transplant
  • Medical Biotechnology
  • Targeted Therapy
  • World
  • Product Initiative
  • Target
  • Target

HEART TRANSPLANT REJECTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2017* CLINICAL TRIALS BY END POINT STATUS HEART TRANSPLANT REJECTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2017* HEART TRANSPLANT REJECTION

  • Cardiovascular Drug
  • Clinical Trial
  • Targeted Therapy
  • Transplantation
  • Novartis AG
  • DORMANT PRODUCTS, H2 2018 (CONTD..1), H2 2018

## ## ## Universities/ Institutes ## ## ## ## ## ## PRODUCTS UNDER DEVELOPMENT BY INDICATION NUMBER OF PRODUCTS UNDER DEVELOPMENT BY TOP ## INDICATIONS, H## 2018 NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H## 2018 Indication Source: Global Markets Dire

  • Immunotherapy
  • Monoclonal Antibody
  • Oncology
  • Targeted Therapy
  • Apexigen, Inc.

The prominent features of this report are - ##.

  • Cardiovascular Drug
  • Medical Biotechnology
  • Nuclear Imaging Equipment
  • Targeted Therapy
  • World

FACTORS CAUSING HEART FAILURE Heart failure can affect one or both the sides of the heart.

  • Beta-Blocker
  • Cardiovascular Drug
  • Amgen Inc.
  • AstraZeneca PLC
  • Novartis AG

CLINICAL TRIALS BY PHASE IN G## COUNTRIES LUNG TRANSPLANT REJECTION THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* LUNG TRANSPLANT REJECTION THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* LUNG TRANSPLANT REJECTION THERAPEUTICS, G## COUNTRIES, CLINIC

  • Cardiovascular Drug
  • Clinical Trial
  • Monoclonal Antibody
  • Targeted Therapy
  • Novartis AG

The prominent features of this report are - ##.

  • Clinical Trial
  • Targeted Therapy
  • World
  • Product Initiative
  • Conatus Pharmaceuticals Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Autoimmune Disease
  • Medical Biotechnology
  • Targeted Therapy
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Cardiovascular Drug
  • Clinical Trial
  • Ophthalmology
  • Targeted Therapy
  • Novartis AG
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2019 (CONTD..4), H1 2019
  • DORMANT PRODUCTS, H1 2019 (CONTD..1), H1 2019

MP## is currently in phase ##.

  • Immunotherapy
  • Targeted Therapy
  • World
  • Product Initiative
  • Apexigen, Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Medical Biotechnology
  • Neurological Disorder
  • Targeted Therapy
  • World
  • Product Initiative
  • DORMANT PRODUCTS, H2 2019 (CONTD..1), H2 2019

## Total ## Products in Phase II/ III and I/ II are reflected under Phase III and Phase II, respectively Source: Global Markets Direct NUMBER OF PRODUCTS UNDER DEVELOPMENT BY STAGE OF DEVELOPMENT, H## 2019 Stage of Development Number of Products Under Development PRODUCTS UNDER DEVELO

  • Immunotherapy
  • Monoclonal Antibody
  • Oncology
  • Targeted Therapy
  • Apexigen, Inc.

Reddy' s Under Fasting Conditions GDCT## NCT##, BA## Immunology Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection Completed Phase I Interventional tacrolimus Dr.

  • Cardiovascular Drug
  • Clinical Trial
  • Targeted Therapy
  • Transplantation
  • Novartis AG

To diagnose coronary artery disease To detect heart transplant rejection Identify right heart failure To measure chemotherapy cardiac toxicity Diagnose acute heart attacks before enzyme changes To evaluate valvular heart disease To select patients for bypass surge

  • Nuclear Imaging Equipment
  • World
  • Digirad Corporation
  • GE Healthcare Limited
  • Koninklijke Philips N.V.

GDCT ID is the unique ID of GlobalData' s Pharma Intelligence Center clinical trial database Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Biomarker(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor

  • Cardiovascular Drug
  • Monoclonal Antibody
  • Pharmaceutical
  • Targeted Therapy
  • World
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Cardiovascular Drug
  • Targeted Therapy
  • World
  • Product Initiative
  • Novartis AG

Significant survival advantages for the abatacept group were demonstrated at one-year post-transplant.

  • Arthritis
  • Immunotherapy
  • Targeted Therapy
  • Therapy
  • Bristol-Myers Squibb Company

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## Alexion Pharmaceuticals Inc ## ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## ## Cytokinetics Inc ## ## ## ## ## ## ## Quintiles IMS Holdings Inc ## ## ## ## ## ## ## CuraVac Inc ## ## ## ## ## ## ## CSL Ltd ##

  • Cardiovascular Drug
  • Monoclonal Antibody
  • Targeted Therapy
  • World
  • Product Initiative

Reddy' s Under Fasting Conditions GDCT## NCT##, BA## Immunology Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection Completed Phase I Interventional tacrolimus Dr.

  • Cardiovascular Drug
  • Clinical Trial
  • Liver Transplant
  • Targeted Therapy
  • Novartis AG

The prominent features of this report are - ##.

  • Cardiovascular Drug
  • Digestive System Disorder
  • Targeted Therapy
  • World
  • Product Initiative

Hoffmann-La Roche Ltd ## ## ## ## ## ## Clinical Research and Biosciences India Private Limited (Inactive) ## ## ## ## ## ## ClinAssess GmbH ## ## ## ## ## ## Bavarian Nordic A/ S ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## APT

  • Medical Biotechnology
  • Pharmaceutical
  • Targeted Therapy
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Blood Disease
  • Clinical Trial
  • Leukemia
  • Targeted Therapy
  • Novartis AG
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Hoffmann-La Roche Ltd arGEN-X BV ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Applied BioMath LLC ## ## ## ## ## Amgen Inc ## ## ## ## ## Almirall SA Source: GlobalData' s Pharma Intelligence C

  • Autoimmune Disease
  • Medical Biotechnology
  • Targeted Therapy
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.
  • Clinical Trial Profile Snapshots

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## ## Johnson & Johnson ## ## ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## ## ## Takeda Pharmaceutical Co Ltd ## ## ## ## ## ## ## ## Incyte Corp ## ## ## ## ## ## ## ## Bellicum Pharmaceuticals Inc ## ##

  • Cardiovascular Drug
  • Pharmaceutical
  • Targeted Therapy
  • United States
  • World
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Drug
  • Monoclonal Antibody
  • Nuclear Imaging Equipment
  • Targeted Therapy
  • World

## ## ## ## ## ## Pfizer Inc Stealth BioTherapeutics Inc Prolong Pharmaceuticals LLC ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Minapharm Pharmaceuticals & Chemical Industries ## ## ## ## ## ## ## Merck & Co Inc ## ##

  • Cardiovascular Drug
  • Monoclonal Antibody
  • Nuclear Imaging Equipment
  • Targeted Therapy
  • World
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Hoffmann-La Roche Ltd ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## Pharmaceutical Product Development LLC ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## Bristol-Myers Squibb Co ## ## ## ## ## ## MallInckrodt Plc ## ## ## ## ## ## CSL Ltd ## ## ## ## ##

  • Autoimmune Disease
  • Pharmaceutical
  • Targeted Therapy
  • Therapy
  • Novartis AG

An Open Labelled Randomized Everolimus Vs Calcineurin Inhibitors Multicenter Trial (CERTICOEUR) A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients.

  • Clinical Trial
  • Skin Cancer
  • Targeted Therapy
  • World
  • Product Initiative

Boehringer Sohn AG & Co KG ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Biogen Inc Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2018 2018 trials are taken as

  • Cardiovascular Drug
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Merck & Co., Inc.